Management of sulfur mustard-induced chronic pruritus: A review of clinical trials

Cutaneous and Ocular Toxicology

Volumn 31, Issue 3, 2012, Pages 220-225

  Panahi, Yunes ^a   Sarayani, Amir ^b   Beiraghdar, Fatemeh ^a   Amiri, Mojtaba ^a   Davoudi, Seyed Masoud ^a   Sahebkar, Amirhossein ^a,c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; Pruritus; Sulfur mustard

Indexed keywords

BETAMETHASONE; CAPSAICIN; DOXEPIN; HYDROXYZINE; MENTHOL; MUSTARD GAS; PHENOL; PIMECROLIMUS; PLACEBO;

APPLICATION SITE VESICLE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG STRUCTURE; DRY SKIN; ERYTHEMA; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN BURNING SENSATION; SKIN EXFOLIATION; SLEEP TIME; SYSTEMATIC REVIEW; WAKEFULNESS;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; MUSTARD GAS; PRURITUS;

EID: 84865323473     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.631655     Document Type: Review

References (52)

1. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34, 000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003;45:1136-1143. (Pubitemid 37420858)
2. Ghabili K, Agutter PS, Ghanei M, Ansarin K, Shoja MM. Mustard gas toxicity: the acute and chronic pathological efects. J Appl Toxicol 2010;30:627-643.
3. Shakarjian MP, Heck DE, Gray JP, Sinko PJ, Gordon MK, Casillas RP et al. Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure. Toxicol Sci 2010;114:5-19.
4. Balali-Mood M, Hefazi M. Comparison of early and late toxic efects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006;99:273-282. (Pubitemid 44578902)
5. Kehe K, Tiermann H, Balszuweit F, Eyer F, Steinritz D, Zilker T. Acute efects of sulfur mustard injury-Munich experiences. Toxicology 2009;263:3-8.
6. Chilcott RP, Jenner J, Carrick W, Hotchkiss SA, Rice P. Human skin absorption of Bis-2-(chloroethyl)sulphide (sulphur mustard) in vitro. J Appl Toxicol 2000;20:349-355.
7. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology 2005;214:198-209. (Pubitemid 41406260)
8. Ghanei M, Poursaleh Z, Harandi AA, Emadi SE, Emadi SN. Acute and chronic efects of sulfur mustard on the skin: a comprehensive review. Cutan Ocul Toxicol 2010;29:269-277.
9. Emadi SN, Mortazavi M, Mortazavi H. Late cutaneous manifestations 14 to 20 years after wartime exposure to sulfur mustard gas: a long-term investigation. Arch Dermatol 2008;144: 1059-1061.
10. Panahi Y, Davoudi SM, Sadr SB, Naghizadeh MM, Mohammadi-Mofrad M. Impact of pruritus on quality of life in sulfur mustard-exposed Iranian veterans. Int J Dermatol 2008;47:557-561. (Pubitemid 351676493)
11. Kehe K, Balszuweit F, Steinritz D, Tiermann H. Molecular toxicology of sulfur mustard-induced cutaneous infammation and blistering. Toxicology 2009;263:12-19.
12. Rice P. Sulphur mustard injuries of the skin. Pathophysiology and management. Toxicol Rev 2003;22:111-118. (Pubitemid 38401301)
13. Kan RK, Pleva CM, Hamilton TA, Anderson DR, Petrali JP. Sulfur mustard-induced apoptosis in hairless guinea pig skin. Toxicol Pathol 2003;31:185-190. (Pubitemid 36374007)
14. Shohrati M, Davoudi M, Almasi M, Sadr B, Peyman M. Comparative study of Unna's Boot and betamethasone cream in the treatment of sulfur mustard-related pruritus. Cutan Ocul Toxicol 2007;26:303-309. (Pubitemid 350208871)
15. Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 2007;26:249-255. (Pubitemid 47237802)
16. Han S, Espinoza LA, Liao H, Boulares AH, Smulson ME. Protection by antioxidants against toxicity and apoptosis induced by the sulphur mustard analog 2-chloroethylethyl sulphide (CEES) in Jurkat T cells and normal human lymphocytes. Br J Pharmacol 2004;141:795-802. (Pubitemid 38446180)
17. Laskin JD, Black AT, Jan YH, Sinko PJ, Heindel ND, Sunil V et al. Oxidants and antioxidants in sulfur mustard-induced injury. Ann N Y Acad Sci 2010;1203:92-100.
18. Jin X, Ray R, Leng Y, Ray P. Molecular determination of laminin-5 degradation: a biomarker for mustard gas exposure diagnosis and its mechanism of action. Exp Dermatol 2008;17:49-56. (Pubitemid 350269212)
19. Arroyo CM, Schafer RJ, Kurt EM, Broomfeld CA, Carmichael AJ. Response of normal human keratinocytes to sulfur mustard (HD): cytokine release using a non-enzymatic detachment procedure. Hum Exp Toxicol 1999;18:1-11. (Pubitemid 29054466)
20. Lardot C, Dubois V, Lison D. Sulfur mustard upregulates the expression of interleukin-8 in cultured human keratinocytes. Toxicol Lett 1999;110:29-33. (Pubitemid 29502424)
21. Sabourin CL, Petrali JP, Casillas RP. Alterations in infammatory cytokine gene expression in sulfur mustard-exposed mouse skin. J Biochem Mol Toxicol 2000;14:291-302.
22. Wormser U, Brodsky B, Proscura E, Foley JF, Jones T, Nyska A. Involvement of tumor necrosis factor-alpha in sulfur mustard-induced skin lesion; efect of topical iodine. Arch Toxicol 2005;79:660-670. (Pubitemid 41618949)
23. Ishida H, Ray R, Ray P. Sulfur mustard downregulates iNOS expression to inhibit wound healing in a human keratinocyte model. J Dermatol Sci 2008;49:207-216. (Pubitemid 351179209)
24. Ghazanfari T, Yaraee R, KiaSalari Z, Ghasemi H, Pourfarzam SH, Soroush MR et al. Evaluation of serum levels of nitric oxide in chemical victims of Sardsht 20 years after sulfure mustard exposure. Iran J War Public Health 2009;1:9-23.
25. Balali-Mood M, Navaeian A. (1986). Clinical and paraclinical fndings in 233 patients with sulfur mustard poisoning. In: Heyndrickx B, ed. Proceedings of the Second World Congress on New Compounds in Biological and Chemical Warfare. Ghent: Rijksuniversiteit, 464-73.
26. Hefazi M, Maleki M, Mahmoudi M, Tabatabaee A, Balali-Mood M. Delayed complications of sulfur mustard poisoning in the skin and the immune system of Iranian veterans 16-20 years after exposure. Int J Dermatol 2006;45:1025-1031. (Pubitemid 44317113)
27. Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005;19:713-721. (Pubitemid 43822007)
28. Ghassemi-Broumand M, Aslani J, Emadi SN. Delayed ocular, pulmonary, and cutaneous complications of mustards in patients in the city of Sardasht, Iran. Cutan Ocul Toxicol 2008;27: 295-305. (Pubitemid 352767480)
29. Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. Arch Dermatol 1992;128:775-780.
30. Rowell M, Kehe K, Balszuweit F, Tiermann H. Te chronic efects of sulfur mustard exposure. Toxicology 2009; 263:9-11.
31. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specifc C-receptors for itch in human skin. J Neurosci 1997;17:8003-8008. (Pubitemid 27426235)
32. Steinhof M, Bienenstock J, Schmelz M, Maurer M, Wei E, Bíró T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006;126:1705-1718. (Pubitemid 44102116)
33. Greaves MW. Pathogenesis and treatment of pruritus. Curr Allergy Asthma Rep 2010;10:236-242.
34. Schmelz M. Itch-mediators and mechanisms. J Dermatol Sci 2002;28:91-96.
35. Gooding SM, Canter PH, Coelho HF, Boddy K, Ernst E. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010;49:858-865.
36. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. Te efect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001;45:910-913. (Pubitemid 33096633)
37. Panahi Y, Davoodi SM, Khalili H, Dashti-Khavidaki S, Bigdeli M. Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure. Singapore Med J 2007;48:392-395. (Pubitemid 351235385)
38. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB. Activation of epidermal vanilloid receptor-1 induces release of proinfammatory mediators in human keratinocytes. J Pharmacol Exp Ter 2003;304:217-222. (Pubitemid 36008931)
39. Panahi Y, Moharamzad Y, Beiraghdar F, Naghizadeh MM. Comparison of clinical efcacy of topical pimecrolimus with betamethasone in chronic skin lesions due to sulfur mustard exposure: a randomized, investigator-blind study. Basic Clin Pharmacol Toxicol 2009;104:171-175.
40. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthof F et al. A novel anti-infammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-273. (Pubitemid 29397994)
41. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-840. (Pubitemid 34494024)
42. Wellington K, Spencer CM. Sdz asm 981. BioDrugs 2000;14:409-416. (Pubitemid 32105548)
43. Eichenfeld LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-1168.
44. Wollina U. Te role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007;8: 157-173. (Pubitemid 46998543)
45. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A. A novel anti-infammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-576. (Pubitemid 27469508)
46. Panahi Y, Davoudi SM, Moharamzad Y, Beiraghdar F, Naghizadeh MM. Comparison of topical capsaicin and betamethasone in the treatment of chronic skin lesions due to sulfur mustard exposure. Cutan Ocul Toxicol 2008;27:203-211.
47. Surh Y. Molecular mechanisms of chemopreventive efects of selected dietary and medicinal phenolic substances. Mutat Res 1999;428:305-327. (Pubitemid 29389702)
48. Burks TF, Buck SH, Miller MS. Mechanisms of depletion of substance P by capsaicin. Fed Proc 1985;44:2531-2534. (Pubitemid 15017049)
49. Greaves MW, Wall PD. Pathophysiology of itching. Lancet 1996;348:938-940. (Pubitemid 26333854)
50. Rumsfeld JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. DICP 1991;25:381-387.
51. Weisshaar E, Kucenic MJ, Fleischer AB Jr. Pruritus: a review. Acta Derm Venereol Suppl (Stockh) 2003:5-32. (Pubitemid 36629840)
52. Weisshaar E, Heyer G, Forster C, Handwerker HO. Efect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res 1998;290:306-311. (Pubitemid 28369387)